drugset
Drugs / Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine
last change Aug 2020 re-read 9 days ago

Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine

also known as aQIV · aIIV4

Vaccine

Developed for
influenza
Investigated by
Seqirus · Novartis Vaccines

Trials 2

today NCT02255409 · Ph 3 NCT01964989 · Ph 3
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02255409 Oct 2014 → Jan 2016 influenza Seqirus Completed No outcome recorded
Phase 3 NCT01964989 Nov 2013 → Oct 2015 influenza Seqirus Completed Missed primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02255409 ↗
1

NCT01964989 ↗
Known as aIIV4 “an MF59-adjuvanted quadrivalent influenza vaccine (aIIV4)” PMID 32404782 ↗ Aug 2020
Known as aQIV “Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)” NCT02255409 ↗
1

“Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)” NCT01964989 ↗
Modality Vaccine “an MF59-adjuvanted quadrivalent influenza vaccine (aIIV4)” PMID 32404782 ↗ Aug 2020
Route Intramuscular “All vaccinations were administered intramuscularly” PMID 29631857 ↗ Apr 2018